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Objectives: The aim of this study was to analyze the technical success and long-term patency of the endovascular treatment
of TransAtlantic Inter-Society Consensus (TASC) C and D aorto-iliac arterial lesions.
Methods: All studies reporting original series of patients published in English between 2000 and 2010 were enrolled into
meta-analysis. Separate meta-analyses were performed for groups with immediate technical success, 12-month patency,
and long-term outcomes. Subgroup analyses were performed to determine if there were differences in outcomes between
patients with varying types of lesions (TASC C or D lesions) or between different stenting strategies, including primary
or selective stenting.
Results: Sixteen articles consisting of 958 patients were enrolled in this meta-analysis. The pooled estimate for technical
success was 92.8% (95% confidence interval [CI], 89.8%-95.0%, 749 cases). Primary patency at 12 months was 88.7%
(95% CI, 85.9%-91.0%, 787 cases). Subgroup analyses demonstrated a technical success rate of 93.7% (95% CI,
88.9%-96.5%) and a 12-month primary patency rate of 89.6% (95% CI, 84.8%-93.0%) for TASC C lesions. For TASC D
lesions, these rates were 90.1% (95% CI, 76.6%-96.2%) and 87.3% (95% CI, 82.5%-90.9%), respectively. The technical
success and 12-month primary patency rates for primary stenting were 94.2% (95%CI, 91.8%-95.9%) and 92.1% (95%CI,
89.0%-94.3%), respectively; for selective stenting, these rates were 88.0% (95% CI, 67.9%-96.2%) and 82.9% (95% CI,
72.2%-90.0%), respectively. The long-term, primary patency rates for patients receiving primary stenting were signifi-
cantly better than those receiving selective stenting. Publication bias was not significant for these analyses.
Conclusions: This study demonstrates that early and midterm outcomes of endovascular treatment for TASC C and D
aorto-iliac lesions were acceptable, with a better patency for primary stenting than selective stenting. (J Vasc Surg 2011;
53:1728-37.)
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BFor patients with aorto-iliac occlusive disease, revascu-
larization is the primary method for treating intermittent
claudication or critical limb ischemia. According to the
From the Department of Vascular Surgery, Peking Union Medical College
Hospital, Chinese Academy of Medical Science and Peking Union Med-
ical College, Beijinga; the Vascular Surgery Department, J. Bernard Hos-
pital, University of Poitiers, Poitiersb; the Department of Surgical Sci-
ences, Section of Vascular Surgery, Uppsala University, Uppsalac; and the
Department of Statistics, Chinese Academy of Medical Science and Pe-
king Union Medical College, Beijing.d
Competition of interest: none.
Reprint requests: Chang-Wei Liu, MD, Department of Vascular, Surgery,
Peking Union Medical College Hospital, Chinese Academy of Medical
Science and Peking, Union Medical College, Beijing, 100730, China
(e-mail: liucw@vip.sina.com).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00t
Copyright © 2011 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2011.02.005
1728ransAtlantic Inter-Society Consensus (TASC), open sur-
ery is the first choice for treatment of long occlusive
esions. Major changes in lesion classification came with the
elease of TASC II in 2007,1 reflecting the rapid growth of
ndovascular treatment. More and more centers have re-
orted satisfactory results with endovascular treatment for
ong segment aorto-iliac occlusive lesions.2-5
The aim of this study was to evaluate the outcomes of
ndovascular treatment (EVT) for aorto-iliac TASC C and
ASC D lesions by performing a systematic review and a
eta-analysis of the technical success and midterm patency
f these procedures. In addition, the influence of lesion
lassification and stenting strategy on the outcome was
nalyzed.
ATERIAL AND METHODS
Literature search strategy. The MEDLINE and EM-
ASE databases were searched for articles published be-
ween January 2000 and January 2010, and the search
l
i
u
s
w
r
c
i
t
v
n
c
p
s
a
b
p
p
a
u
U
w
C
t
t
t
a
e
R
L
a
m
m
n
m
T
r
S
r
s
p
f
d
d
a
r
M
r
m
o
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 6 Ye et al 1729was restricted to articles published in English. The fol-
lowing keyword combinations were used for both data-
bases and the results combined: “iliac artery occlusion”,
“endovascular”, “endoluminal”, “aorto-iliac artery occlu-
sion”, “TASC C”, and “TASC D”. Additional “related
articles” suggested by MEDLINE or EMBASE, refer-
ence lists of retrieved articles, and reviews on the subject were
also evaluated to identify any additional relevant published
studies.
Study selection. Studies were included in the analysis
if they gave details of patients undergoing EVT as well as
their outcomes (immediate technical success and primary
patency). Articles were rejected if they contained no pri-
mary data, contained data previously reported in other
articles, or contained less than 10 cases. If an article in-
cluded the analysis of both open surgery and EVT or data
that included other lesion types, it was included only if
major outcomes for EVT of TASC C and TASC D lesions
could be accounted for separately. Studies that did not use
the TASC classification or that were presented as reviews,
meta-analyses, or conference abstracts were also excluded.
Study selection was performed by two independent
reviewers (W.Y., R.Z.), and any discrepancies were resolved
by a consensus among the six authors.
Data extraction. The two major endpoints assessed in
this study were the immediate technical success rates of
EVT on TASC C or TASC D aorto-iliac lesions (defined as
achieving a residual stenosis of less than 30% after angio-
plasty or stenting) and the primary patency rates at 12-
month intervals. As all studies were based on cases reported
rather than on specific limbs, major endpoints were assessed
on a per-patient basis. Secondary patency rates at 12
months and long-term primary and secondary patency rates
between 12 and 60 months were also extracted from these
articles. EVT related mortality and complications were also
evaluated. Two covariates, lesion classification according to
TASC classification and stenting strategy (primary or selec-
tive), were extracted from each study for the purpose of
determining whether they had any effect on patient out-
comes. All figures quoted as percentages were converted
back to numerators and denominators prior to analysis.
Discrepancies between data extracted at two time points
were resolved by a consensus among all authors.
Statistical methods. Meta-analyses were performed
on the two major endpoints, immediate technical success
rate and primary patency rate. We conducted individual
meta-analyses on primary patency at 12 months and at each
successive time point with 12-month increments (12, 24,
36, 48, and 60months) to determine whether patency rates
varied during follow-up. The same procedure was per-
formed for secondary patency rates. Perioperative mortality
and complications were also evaluated. All data extracted
were presented as rates and were converted to a log odds
scale for subsequent meta-analysis.
Meta-analyses were performed using random effects
models in all cases. Random effects models were used, as
the intra-study variation (heterogeneity) was significant in
most tests (P.05), and fixed effect models would thus be fess suitable. The presence of heterogeneity between stud-
es was determined using the -square test and quantified
sing I.6 Weighted random effects linear regression analy-
es were performed for the two primary outcome measures
ith the mid-date of the study (the date midway from the
eported start of the study to the end of the study) as the
ovariate, to determine whether there had been any change
n the outcome measures over time. Each study included in
he regression analysis was weighted by the inverse of its
ariance. This was decided because of the high variation of
umber of cases among the analyzed studies (minimum 11
ases, maximum179 cases). To investigate the possibility of
ublication bias in the literature, funnel plots were con-
tructed and examined visually for asymmetry. In cases of
symmetry, less precise studies were identified toward the
ottom of the funnel plots and removed from analysis. The
rimary meta-analyses were repeated using only the more
recise studies located near the top of the plot for which
symmetry was not evident. Meta-analyses were performed
sing ReviewManager (version 5; Cochrane IMS, London,
nited Kingdom), and regression analyses were performed
ith Prism (version 5.03; GraphPad Software Inc, La Jolla,
alif). All results were converted back to percentages for
he ease of interpretation. The Meta-Analyses of Observa-
ional Studies (MOOSE) statement guidelines were used in
he design, conduct, and reporting of this study7. One of
uthors (J.J.), a statistician, was in charge of all statistical
valuations.
ESULTS
iterature search
A total of 596 articles were identified. From these, 16
rticles providing sufficient data concerning the two
ajor endpoints were identified and selected for this
eta-analysis. Within these articles, 13 addressed tech-
ical success, 12 addressed primary patency at 12
onths, and 12 addressed long-term primary patency.
he study flow chart (Fig 1) gives details concerning the
ationale for rejecting studies.
tudy characteristics
The 16 articles included data from 958 patients who
eceived EVT for TASC C or TASC D aorto-iliac le-
ions.8-23 The time period during which these studies took
lace was from 1993 to 2008, with publication varying
rom 2003 to 2010. Characteristics of these articles are
etailed in Table I. Within these 16 articles, 12 included
ata from a single center, 3 included data from 2 centers,
nd 1 included data from 3 centers. All 16 studies were
etrospective.
eta-analysis
Primary outcome. Separate meta-analyses were car-
ied out for the two primary outcome measures. The im-
ediate procedural technical success rate after angioplasty
r stenting was reported in 13 studies and included data
rom 749 patients.8-10,13-18,20-23 The pooled estimate for
Inter-Society Consensus (TASC) C and D aorta-iliac lesions.
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June 20111730 Ye et alTable I. Summary of the 16 studies included in the meta-analysis
Study
(reference
number)
Midterm of
study
Centersa
(n)
Patients
(n)
TASC C
(n)
TASC D
(n)
Symptoms
(%)
Strategy of
stenting
Technical
success rate
Primary
patency
(1 year)
Maximum
length of
follow-up
(months)
AbuRahma8 Jan-2003 1 62 Not statedb Not statedb Not stated 49 cases
primary
93% 96% 36
13 cases
selective
46% 46% 36
Ahn9 Mar, 1999 1 41 36 5 Not stated Selective 97.60% Not stated
Balzer10 July, 2000 2 89 37 52 IC 88.8%
CLI 11.2%
Primary 96.90% 95% 36
Björses11 June 2000 3 89 18 71 Not stated Primary Not stated 93% 36
Do12 Nov, 1999 1 48 32 16 Not stated Primary Not stated 94% 60
Hans13 Dec, 2002 2 40 27 13 Not stated Primary 95% 87% 48
Jackson14 Nov, 2001 2 22 Not statedb Not statedb CLI 100% Primary 95.45% 84.40% 24
Kashyap15 Oct, 2000 1 67 30 37 IC 46.6%
CLI 53.4%
Primary 89.60% 94% 36
Krankenberg16 Dec, 2005 1 11 0 11 IC 91%
CLI 9%
Selective 100% Not stated
Kumakura17 Dec, 2000 1 88 33 55 IC 45%
CLI 55%
Selective 89.60% 86% 72
Moise18 June 2003 1 31 0 31 Not stated Selective 93% 85% 36
Ozkan19 May, 2005 1 72 25 47 Not stated Primary Not stated Not stated 60
Piffaretti20 Dec, 2001 1 43 34 9 IC 62.8%
CLI 37.2%
Selective 100% 92% 60
Powell21 Oct, 2000 1 29 15 14 Not stated Primary 100% 87.70% 12
Sixt22 Oct, 2000 1 179 113 66 IC 80%
CLI 20%
Selective 95.60% 86% 60
Sharafuddin23 Oct, 2000 1 47 Not statedb Not statedb Not stated Primary 91.50% Not stated
CLI, Critical limb ischemia; IC, intermittent claudication; TASC, TransAtlantic Inter-Society Consensus.
aAll studies were retrospective.
bFig 1. Study flow chart of the study selection for meta-analysis on endovascular treatment for TransAtlanticTASC classification used in the article and all patients included in the meta-analysis have TASC C or TASC D aorto-iliac lesions, but the distribution between
these two classes was not stated in the article.
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Volume 53, Number 6 Ye et al 1731technical success rate in these studies was 92.8% (95%
confidence interval [CI], 89.8%-95.0%, I2  34%) (Fig 2).
The pooled estimate for the 12-month primary patency rate
(12 studies, 787 patients)8,10-15,17-18,20-22 was 88.7% (95%
CI, 85.9%-91.0%, I2 14%) (Fig 3). Both analyses showed
moderate to large heterogeneity between studies, as indi-
cated by the I2-values. Studies giving details regarding
primary patency at 12-month intervals were entered into an
individual meta-analysis for each of the following time-
points: 12, 24, 36, 48, and 60 months (Table II).
Secondary outcome.
Secondary patency rate. Six articles10,12,15,18,21,22
(443 cases) reported 12-month secondary patency rates.
Meta-analyses of the 12-, 24-, 36-, 48-, and 60-month
secondary patency rates are presented in Table III.
Perioperative mortality. Six articles8,13,16,18,20,23
(234 cases) provided data on perioperative mortality. One
article23 reported three deaths at 30 days from a total of 47
patients treated. In this series, one patient died from severe
sepsis, one patient died from arrhythmic cardiac arrest, and
one patient died from myocardial infarction. The mortality
of the other five articles8,13,16,18,20 was nil, and the mortal-
ity rate of all patients entered in these six studies was 2.9%
(95% CI, 2.4%-3.4%).
Perioperative complications. Sevenarticles8,10,13,16,18,20,23
(323 cases) reported perioperative complications. In total,
39 complications occurred. The complication rate was
15.3% (95% CI, 11.5%-20%). Twelve complications were
related to the access route and mostly occurred in cases
utilizing the brachial artery route. Embolism or thrombo-
Fig 2. Pooled estimate for technical success rate (13 s
interpretability).embolism of the target arteries or distal arteries occurred in l3 patients, flow-limiting dissections in 4 patients, con-
rast-induced nephropathy in 6, rupture of the iliac artery in
, and hypovolemic shock and stroke in 1 patient.
egression analyses
Separate regression analyses were performed for the
wo primary outcomes. The mid-date of each study was
sed as a covariate to determine whether there had been
ny change in technical success or 12-month primary pa-
ency over time. Twenty-four-month and 36-month pri-
ary patency rates were also analyzed using time regression
nalysis. The results showed no significant association be-
ween the mid-date of the study and the technical success
ate (F  .03553, P  .854); however, a significant associ-
tion was found between the mid-date of the study and
2-month primary patency rate (F  .638, P  .0308).
hen analyzing the 12-month patency rate based on the
id-date of the study, the 12-month patency was lower in
he later studies compared with the prior studies. The
2-month patency rate declined by 2% (95% CI, 0.2%-3%)
or each year’s increase in study mid-date (which varied
rom 1999 to 2003). Interestingly, no significant associa-
ion was found between the mid-date of the study and
4-month or 36-month primary patency rates (F  3.205,
 .107) and (F  2.568, P  .148), respectively.
Subgroup analyses. Subgroup analyses were per-
ormed to determine if there were different outcomes be-
ween patients with varying types of lesions (TASC C or
ASC D lesions) or between different strategies, including
rimary or selective stenting. In this analysis, TASC D
s 749 cases) (plotted on proportional scale for ease oftudieesions had a lower technical success rate and a lower
m
a
m
r
s
JOURNAL OF VASCULAR SURGERY
June 20111732 Ye et alprimary patency rate at 12-month than TASC C lesions,
but this difference was not significant. Primary stenting was
found to have a higher technical success rate and a higher
12-month primary patency rate than selective stenting
(Table IV), but again, this difference was not statistically
significant.
Fig 3. Pooled estimate for the 12-month primary patenc
Table II. Primary patency rates at every 12-month period
Time-period
(months)
Studies
(n)
Patients
(n)
Primary
patency (%)
Prim
patenc
CI (int
12 12 787 88.7 85.9
24 11 758 81.9 77.1
36 10 736 76.5 69.2
48 5 398 70.4 57.4
60 5 430 64 53.5
CI, Confidence interval.ease of interpretability).We also compared the primary patency rate at 12-
onth intervals between TASC C and TASC D lesions
ccording to the stenting strategy. These results are sum-
arized in Table V. Over the first 4 years, primary stenting
esulted in a patency rate that was 10% higher than selective
tenting. This difference was statistically significant at 24
(12 studies 787 cases) (plotted on proportional scale for
dom effects models)
) Statistical analysis: Test used and P value
0 Heterogeneity: 2 0.03; 2  12.76, Df 11 (P  .31);
I2  14%
Test for overall effect: Z  15.86 (P .00001)
0 Heterogeneity: 2 0.13; 2  22.72, df 10 (P  .01);
I2  56%
Test for overall effect: Z  9.85 (P .00001)
6 Heterogeneity: 2  0.26; 2  37.90, df  9 (P 
.0001); I2  76%
Test for overall effect: Z  6.22 (P .00001)
7 Heterogeneity: 2  0.32; 2  21.69, df  4 (P 
.0002); I2  82%
Test for overall effect: Z  3.01 (P  .003)
4 Heterogeneity: 2  0.18; 2  16.57, df  4 (P 
.002); I2  76%
Test for overall effect: Z  2.57 (P  .01)y rate(ran
ary
y 95%
erval
91.
86.
82.
80.
73.
As
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showed comparable patency (67.1% vs 63.0%). The differ-
ences for every 12-month patency rate between TASC C
and TASC D were not significant, although TASC C
Table III. Secondary patency at every 12-month interval (
Time-period
(months)
Studies
(n)
Patients
(n)
Secondary
patency (%)
Sec
pate
C
12 6 443 95.4 92.8
24 4 230 91.7 86.8
36 4 235 91.0 86.4
48 1 40 89.1 75.1
60 2 91 83.0 73.0
CI, Confidence interval.
Table IV. Outcomes analysis by subgroups
Technical success
Subgroups Subgroups
Studies
(n)
Patients
(n)
Techni
success (
TASC classification TASC C 3 176 93.7
TASC D 3 158 90.1
Stenting primary vs
secondary
Primary 9 565 94.2
Selective 5 184 88
12 months primary patency
Subgroups Subgroups
Studies
(n)
Patients
(n)
12-m
pri
paten
TASC classification TASC C 6 279 8
TASC D 7 266 8
Stenting primary vs
secondary
Primary stenting 8 433 9
Selective stenting 5 354 8
TASC, TransAtlantic Inter-Society Consensus.showed better results at every time interval. assessment of publication bias
Funnel plots were constructed to assess the technical
uccess rate and primary patency rates at 12 months for
om effects models)
ry
5%
Statistical analysis: Tests used and results
7.1 Heterogeneity: 2  6.81, Df  5 (P  .24); I2 
27%
Test for overall effect: Z  12.21 (P .00001)
5.0 Heterogeneity: 2  6.44, df  3 (P  .09); I2  53%
Test for overall effect: Z  8.92 (P .00001)
4.1 Heterogeneity: 2  2.28, df  3 (P  .52); I2  0%
Test for overall effect: Z  9.89 (P .00001)
5.6 Heterogeneity: not applicable
Test for overall effect: Z  4.14 (P .0001)
9.8 Heterogeneity: 2  3.75, df  1 (P  .05); I2  73%
Test for overall effect: Z  5.29 (P .00001)
Technical
success 95%
CI Statistics: Tests used and results
88.9 96.5 Heterogeneity: 2  0.00; 2  .78, df  2
(P  .68); I2  0%
Test for overall effect: Z  8.51 (P .00001)
76.6 96.2 Heterogeneity: 2  0.48; 2  5.28, df  2
(P  .07); I2  62%
Test for overall effect: Z  4.24 (P .0001)
91.8 95.9 Heterogeneity: 2  0.00; 2  6.31, df  8
(P  .61); I2  0%
Test for overall effect: Z  14.74 (P .00001)
67.9 96.2 Heterogeneity: 2  1.46; 2  18.40, df  4
(P  .001); I2  78%
Test for overall effect: Z  3.15 (P  .002)
)
12-month
primary
patency 95%
CI Statistics: tests used and results
84.8 93.0 Heterogeneity: 2  0.02; 2  5.30, df  5
(P  .38); I2  6%
Test for overall effect: Z  9.78 (P .00001)
82.5 90.9 Heterogeneity: 2  0.00; 2  5.11, df  6
(P  .53); I2  0%
Test for overall effect: Z  10.02 (P .00001)
89.0 94.3 Heterogeneity: 2  0.00; 2  6.51 df  7
(P  .48); I2  0%
Test for overall effect: Z  13.18 (P .00001)
72.2 90.0 Heterogeneity: 2  0.33; 2  13.24, df  4
(P  .01); I2  70%
Test for overall effect: Z  4.97 (P .00001)rand
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tively. The technical success rate and primary patency
rate at 12-month showed symmetric funnel top, meaning
less publication bias in the meta-analysis, and no study
was removed from the analysis.
DISCUSSION
Endovascular treatment of TASC C or TASC D aorto-
iliac lesions has been widely used during the last 10 years.
However, TASC II recommendations regarding EVT state
that for type D lesions, “endovascular methods do not yield
good enough results to justify them as primary treatment”
and for type C lesions, “open revascularization produces
superior long-term results” and “endovascular methods
should only be used when there is high risk associated with
open repair”.1 Because major changes were made between
the TASC I and TASC II classifications,1,24 it seems that
more vascular surgeons are treating TASC C or TASC D
Table V. Subgroup analyses of primary patency rates at ev
Time period
(months)
Subgroup
analysis Studies (n)
Patien
(n)
12 TASC C 6 279
TASC D 7 266
PS 8 433
SS 5 354
24 TASC C 5 166
TASC D 6 200
PS 7 404
SS 5 354
36 TASC C 5 166
TASC D 6 200
PS 6 382
SS 5 354
48 TASC C 3 99
TASC D 3 62
PS 2 88
SS 3 310
60 TASC C 4 124
TASC D 4 109
PS 2 120
SS 3 310
CI, Confidence interval; NS, not significant; PS, primary stenting; SS, select
Fig 4. Funnel plots. Each point represents an individu
estimate for that outcome. a, Immediate technical succelesions with endovascular methods. As such, it was impor- Eant to focus on improvements in EVTs, particularly on the
echnical success rate and primary patency rate.
The high technical success rates confirmed in this study
eflect technical and device improvements in the recent
ears, while the satisfactory primary patency rate observed
eflects the durability of EVT in patients with TASC C or
ASC D lesions. In addition, EVT is considered to be an
asy-to-repeat procedure for re-stenosis, and this could be a
eason for the high rates of secondary patency observed in
his meta-analysis.
Considering technical success, 13 studies examining
49 patients showed a combined technical success rate of
2.8% (95% CI, 89.8%-95.0%). Subgroup analyses demon-
trated some trends showing that TASC C lesions had
etter results than TASC D lesions (93.7% vs 90.1%) and
hat primary stenting results were better than those of
elective stenting (94.2% vs 88%), but these differences
ere not significant. A previous meta-analysis examining
2-month time period (random effects models)
Primary
patency (%)
Primary patency
(%) 95% CI Significance
89.6 84.8 93.0 NS
87.3 82.5 90.9
92.1 89.0 94.3 NS
82.9 72.2 90.0
87.5 73.3 94.6 NS
79.3 70.9 85.7
87.3 83.7 90.3 P .05
72.6 63.6 80.0
79.9 64.8 89.6 NS
76.0 65.0 84.4
82.3 76.3 87.0 P .05
64.9 63.5 74.7
79.2 43.8 94.6 NS
66.2 47.6 80.8
79.1 55.8 91.9 NS
64.4 49.7 76.7
61.8 36.7 81.9 NS
66.6 55.2 76.2
67.1 53.8 78.0 NS
63.0 48.2 72.7
nting; TASC, TransAtlantic Inter-Society Consensus.
dy. The vertical dotted line indicates the overall study
12-month primary patency rate.ery 1
tsal stuVT for iliac lesions25 found an initial technical success rate
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Volume 53, Number 6 Ye et al 1735of 91% for iliac percutaneous transluminal angioplasty
(PTA), and 96% for iliac stenting. Considering that 70%
to 80% of the lesions in these previous meta-analyses
were only stenoses, it seems that a significant improve-
ment in endovascular technique has been made over the
past 10 years. Some authors have reported performing
EVT for total aorto-iliac occlusion,16,26 with technical
success rates varying from 80% to 100%. These findings
suggest that the length and percentage of occlusion are
not the only factors influencing technical success. Other
factors, including the EVT learning curve, should be
considered and studied.
Long-term durability is also an issue when analyzing
the results of EVT for long aorto-iliac segment occlusion.
In this meta-analysis, the 5-year primary patency was 64%
(95% CI, 53.5%-73.4%); well below that of aortobifemoral
bypasses (ABF), which have rates reported to be as high as
80% to 85%.27 However, our meta-analysis showed an
encouraging secondary patency rate of 83.0% at the
5-year mark, indicating a reintervention rate of approxi-
mately 19%. These data regarding EVT are interesting
because secondary intervention for EVT restenosis has
been widely considered as relatively easy and harmless,
with secondary patency rates comparable to that of the
secondary patency observed in the open bypass group
(95% vs 97%).28
When comparing EVT with open surgery, mortality,
and morbidity should also be considered. In this meta-
analysis, the operative mortality of EVT for TASC C and
TASC D aorto-iliac lesions was 2.9% (95% CI, 2.4%-3.4%),
and the complication rate was 15.3% (95%CI, 11.5%-20%).
A prior meta-analysis of 25 articles showed a postoperative
mortality rate of 4.4% and a complication rate of 12.2% for
ABF.27 Due to potential differences in patient selection
when deciding on open or endovascular treatment and
variations in type and severity of complications, a direct
comparison of these results is not possible.
Another outcome analyzed in this meta-analysis was
the result of primary stenting (354 patients) vs selective
stenting (433 patients). Primary stenting was found to be a
better treatment option with a higher technical success rate
as well as a higher long-term patency rate at 1- to 4-year
intervals. The 5-year patency of both groups was compara-
ble, but this may be due to the limited number of studies
available. Based on these findings, we can recommend
primary stenting over selective stenting when treating
TASCC or TASCD aorto-iliac lesions. Comparable results
have been found by AbuRahma et al,8 who reported an
overall early clinical success rate of 93% for primary stenting
vs 46% for selective stenting in TASC C and TASC D iliac
lesions (P .0003). These results are in contrast with those
of the Dutch randomized trial that showed comparable
results between selective and primary stenting;29 however,
this trial excluded most TASC C or TASC D lesions.
Similarly, Cambria et al30 advocated PTA with selective
stenting, but in this series, the average length of stenosis
treated was only 3.3  0.1 cm. Although it would have
been of interest to evaluate the success rate and patency tutcome of stenting vs angioplasty alone for aorto-iliac
ASC C and TASC D lesions, adequate data on this item
as lacking in the evaluated studies. In the 13 articles with
esults on patency, eight articles (433 cases) applied a
rimary stenting strategy, while five articles (354 cases)
erformed primary angioplasty and selective stenting. Only
our of these articles (341 cases) offered more detailed data,
7 cases were treated with angioplasty alone, and 274 cases
ere stented because of unsatisfactory result after angio-
lasty. However, adequate data on outcome of angioplasty
lone was difficult to extract.
Finally, in the subgroup analysis comparing TASC C
nd TASC D lesions, no significant difference was found
etween the two groups, probably because the length of
he occlusion is not the only critical factor when consid-
ring technical success and patency. Other factors such as
he stenting strategy, medication, and inflow and out-
ow conditions may play important roles in these situa-
ions.17,19
It is important to underline that some of the cases in
he current analysis date back to 1993 and that the
idterm of most of the studies is in 2000. This is despite
he fact that 14 out of the 16 articles in this meta-analysis
ere published after 2005, and 11 articles were pub-
ished after the release of the TASC II classification in
007. Thus, further improvements in primary success
nd long-term outcome of endovascular treatment due
o further development of the technique and endovascu-
ar devices is probable.
We recognize, however, that our study has some limi-
ations. All the series analyzed were retrospective, andmany
ame from a single institution. This means that the techni-
al success rate may have been overestimated. It is known
hat many authors are reluctant to report their failures.
dditionally, some journal editors may reject negative re-
orts as they may be deemed uninteresting. This limitation
s widely recognized for meta-analyses. On the other hand,
s large randomized trials are still pending, this meta-
nalysis appeared useful even if derived from simple obser-
ational studies.
A difficulty we faced was the fact that the TASC classi-
cation changed during the time frame over which these
rticles were published. Eleven articles used the TASC I
lassification, three articles used the TASC II classification,
nd two articles did not mention which classification they
eferred to. All studies, however, did use the TASC classi-
cation, and in studies, including cases from the period
efore the publication of the TASC I system, these cases
ad been classified retrospectively. Some TASC I lesions
ay be downgraded using the TASC II system. However,
e did not find significant differences in outcomes between
he two TASC classifications. This is another reason to
onsider that the clinical results of EVT for long occlusive
orto-iliac lesions are not related only to the length of the
rterial occlusion.
Another limitation of this study is that we could not
valuate all the confounding factors that might influence
he outcome because we could not extract enough infor-
11
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1
1
1
1
1
1
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2
2
2
2
2
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June 20111736 Ye et almation concerning patient characteristics such as age, sex,
comorbidity, or stent-type to determine whether these
factors could affect the overall outcome. Importantly, we
were not able to evaluate the outcome based on the clinical
symptoms (claudication vs critical limb ischemia). This is
because only a few articles provided multivariate modeling
analyses of demographic variables to determine their asso-
ciation with patency. In these studies, the risk factors re-
ported as significantly reducing long-term patency include
critical limb ischemia,9 subintimal recanalization,9 and di-
abetes.15,17
Nevertheless, this study demonstrates that outcomes of
endovascular treatment for TASC C and TASC D aorto-
iliac lesions were acceptable with a better patency rate for
primary stenting compared with selective stenting. We did
not find significantly different outcomes between TASC C
and TASC D lesions. Further studies, including large,
multicenter randomized controlled trials, are required be-
fore further conclusions can be made. This meta-analysis
has also shown that to facilitate further interpretation of the
results, it would be useful if future reports on treatment of
aorto-iliac lesions include data on patency related to clinical
symptoms (claudication vs critical limb ischemia) as well as
comorbidities and presence or absence of atherosclerotic
lesions in the arteries distal to the aorto-iliac segment.
The authors thank Wei Han for his assistance in man-
aging the data and all the authors of the enrolled articles for
their coordination with data collection and supplemental
materials.
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